Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas SI, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. · 2020
Read Cholangiocarcinoma 2020: the next horizon in mechanisms and management. by Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas SI, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7447603.txt.
Introduction
Banales and co-authors present an expert consensus on cholangiocarcinoma, a group of bile duct cancers. These tumors arise anywhere along the biliary tree and vary a lot. Their incidence is rising worldwide.
The statement notes that these cancers form about 15% of primary liver cancers and about 3% of gut malignancies in current counts. They cause about 2% of cancer deaths each year. Late, silent symptoms, fierce growth, and drug resistance drive the high death rate. Non-invasive tests are not accurate enough, so tissue proof is needed. The authors sum up new work on classes, origins, gene changes, and biomarkers. They also review treatments and sketch the next decade of research for this hard disease.
Catalog record
| CREATOR | Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas SI, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 184 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Cholangiocarcinoma 2020: the next horizon in mechanisms and management By Jesus M Banales, Jose J G Marin, Angela Lamarca, Pedro M Rodrigues, Shahid A Khan, Lewis R Roberts, Vincenzo Cardinale, Guido Carpino, Jesper B Andersen, Chiara Braconi, Diego F Calvisi, Maria J Perugorria Published in: Nature Reviews. Gastroenterology & Hepatology DOI: 10.1038/s41575-020-0310-z ABSTRACT Abstract Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted. Subject terms: Biliary tract cancer, Cancer INTRODUCTION Cholangiocarcinoma (CCA) constitutes a diverse group of malignancies emerging in the biliary tree. CCAs are divided into three subtypes depending on their anatomical site of origin: intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) CCA1,2 (Fig. 1). Of note, considered as an independent entity, mixed HCC–CCA tumours are a rare type of liver malignancy sharing features of both iCCA and HCC and presenting an aggressive disease course and poor prognosis3,4. iCCAs arise above the second-order bile ducts, whereas the point of anatomical distinction between pCCA and dCCA is the insertion of the cystic duct. pCCA and dCCA can also be collectively referred to as ‘extrahepatic’ (eCCA)5. In the USA, pCCA is the single largest group, accounting for approximately 50–60% of all CCAs, followed by dCCA (20–30%) and iCCA (10–20%)1,6,7. CCA is the second most common primary hepatic malignancy after hepatocellular carcinoma (HCC), comprising approximately 15% of all primary liver tumours and 3% of gastrointestinal cancers1,6,7. CCAs are usually asymptomatic in early stages and, therefore, often diagnosed when the disease is already in advanced stages, which highly compromises therapeutic options, resulting in a dismal prognosis1,8. CCA is a rare cancer, but its incidence (0.3–6 per 100,000 inhabitants per year)1 and mortality (1–6 per 100,000 inhabitants per year, globally9, not taking into account specific regions with incidence >6 per 100,000 habitants such as South Korea, China and Thailand) have been increasing in the past few decades worldwide, representing a global health problem. Despite advances in CCA awareness, knowledge, diagnosis and therapies, patient prognosis has not improved substantially in the past decade, with 5-year survival (7–20%) and tumour recurrence rates after resection still disappointing10–17. Therefore, a detailed study of these types of cancers is urgently needed to improve patient welfare and outcomes. Considering the high heterogeneity of CCAs, individual characterization of these tumours at the genomic, epigenetic and molecular levels is an indispensable approach to ascertain their pathogenesis, paving the path for new therapeutic options and personalized medicine. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma (ENS-CCA), we provide a comprehensive and critical overview of current knowledge and what is envisaged on the horizon for CCA, focusing on epidemiology, risk factors, clinical presentation, diagnosis, genetic and epigenetic landscape, molecular perturbations, chemoresistance and therapies. [Figure: Anatomical classification of cholangiocarcinoma.On the basis of the anatomical site of origin, cholangiocarcinoma (CCA) is classified into intrahepatic CCA (iCCA), perihilar CCA (pCCA) and distal CCA (dCCA). iCCA is defined as a malignancy located in the periphery of the second-order bile ducts, pCCA arises in the right and/or left hepatic duct and/or at their junction, and dCCA involves the common bile duct (that is, the choledochus). Grossly, CCA can show three main patterns of growth: mass-forming, periductal-infiltrating, and intraductal-growing. Mass-forming CCA is a mass lesion in the hepatic parenchyma. Periductal-infiltrating iCCA grows inside the duct wall and spreads longitudinally along the wall. Intraductal-growing CCA is a polypoid or papillary tumour growing towards the duct lumen.] METHODS This international group of multidisciplinary experts in CCA (that is, oncologists, surgeons, hepatologists, geneticists, immunologists, basic scientists) has been intensively collaborating within the ENS-CCA since 2015 with the main aims of improving our understanding of CCA and the management of patients. In this regard, this expert consensus is endorsed by the ENS-CCA. The overall goal of this multidisciplinary statement is to provide a detailed critical overview of the current knowledge in this field, proposing some expert recommendations and highlighting what is envisaged for the next decade. J.M.B. and G.J.G. identified the areas of interest, stratified the consensus statement into the sections presented in the document and assigned them to selected ENS-CCA members or non-European collaborators (L.R.R., S.G., S.I.I., J.H. and G.J.G.) who are expert in each field of knowledge and research. To write this document, a PubMed search was conducted by combining the term ‘cholangiocarcinoma’ with the following terms: ‘epidemiology’, ‘risk factors’, ‘classification’, ‘cells of origin’, ‘diagnosis’, ‘staging’, ‘genetics’, ‘epigenetics’, ‘signalling pathways’, ‘epithelial-to-mesenchymal transition’, ‘cancer stem cells’, ‘tumour microenvironment’, ‘immunobiology’, ‘in vitro and in vivo models’, ‘biomarkers’, ‘surgery’, ‘liver transplantation’, ‘therapies’, ‘clinical trials’ and ‘chemoresistance’. No specific search dates were used. All the sections were merged into a first draft by P.M.R and J.M.B. and then extensively revised to create the final document that was later circulated among all the authors for further correction, improvement, discussion and approval. The data presented in Fig. 2 were obtained by combining the values of mortality rates in men and women for both iCCA and eCCA reported in 2019 by Bertuccio et al.9. For the recommendations on CCA management and research priorities, ideas were proposed, discussed and approved after final revision by all the authors to reach a consensus. [Figure: Mortality of cholangiocarcinoma worldwide.Global age-standardized annual mortality rates for cholangiocarcinoma (CCA) (deaths per 100,000 inhabitants, including intrahepatic CCA, perihilar CCA and distal CCA) obtained from Bertuccio et al.9. Data refer to the periods 2000–2004 (2002), 2005–2009 (2007) and 2010–2014 (2012). Yellow indicates countries/regions with low mortality (<2 deaths per 100,000 people), orange indicates countries/regions with mortality between 2 and 4 deaths per 100,000 people, and red indicates countries/regions with high mortality (>4 deaths per 100,000 people). Mortality in eastern countries/regions in which CCA is highly prevalent (that is, Thailand, China, Taiwan and South Korea) have not yet been reported and, therefore, CCA incidence is shown for these countries1.] EPIDEMIOLOGY AND RISK FACTORS The global mortality for CCA increased worldwide during the periods 2000–2004, 2005–2009 and 2010–2014 (Fig. 2), according to the WHO and Pan American Health Organization databases for 32 selected locations in Europe, America, Asia and Oceania9. Furthermore, CCA mortality was higher in men than in women worldwide, and